第12版基于过往数据回顾和近期临床实践，提供了简单但详细的精神疾病和相关精神药理学的综述。主要介绍血浆药物水平监测、精神分裂症、双向情感障碍、抑郁症、焦虑症、儿童和青少年用药、药物滥用，以及特殊患者群体用药。每部分都有完整的参考文献，以便在需要时可以快速查询证据库。本书还介绍了尚未得到共识的药物治疗，以及药物与乙醇、烟碱和咖啡因的相互作用等方面的内容。

一本为精神疾病患者开具精神科处方药物的参考书。本书被广泛使用，涵盖专业人士需了解的各种相关信息。包括如何开具处方、需要注意的不良反应、如何有效增强药效或更换药物，例如抗精神病药、抗抑郁药和抗焦虑药。初级专业人士通过阅读本书将获得精神疾病用药的基础理论、安全性和疗效方面的重要信息。经验丰富的临床医生将会从本书在他们可能不会经常遇到的更复杂的问题上找到很好的指导。

This 12th edition of The Maudsley Prescribing Guidelines in Psychiatry marks its 20th year in continuous production. Readers who have owned or used previous editions will find this edition no different in style from previous incarnations. This is deliberate – the feedback we receive suggests the organisation and structure are well liked. Each section of The Guidelines is a densely referenced but succinct review of the literature, set alongside some fairly broad recommendations for practice. Each of these sections has been updated and revised, and some new ones added (for example, interpreting clozapine plasma levels, post‐mortem plasma levels, summary of depot pharmacokinetics). Much of the guidance provided in this edition has changed as a result of more recent research; some of it to a small extent, some of it to an extent amounting to a reversal of prior guidance (for example, on the use of fish oils in psychosis). These changes reflect the very nature of the scientific method – that hypotheses come and go as evidence mounts or is countered.

This edition of The Guidelines has a particularly international flavour. This is because the 11th edition sold more copies outside the UK than in it, and because there are, we think, at least ten translations of The Guidelines in existence. Although The Guidelines are still essentially our local guide to prescribing, we have made a special effort to widen, geographically speaking, its utility. This is most noticeable in the inclusion of drugs not licensed in the UK (e.g. ziprasidone, iloperidone, desvenlafaxine), but widely used in other countries. Readers should, therefore, not assume that every drug mentioned in The Guidelines is available in their own country. The reader should also be aware that no guideline could take account of every psychotropic drug used around the world, so omissions are inevitable.

1. As with previous editions, very special thanks are due to Maria O’Hagan who manages the writing and structuring of The Guidelines; an increasingly complex process given the size, complexity and heavily referenced nature of the current edition. Thanks are also due to the many expert contributors to The Guidelines who are listed overleaf, and to Adam Gilbert, our editor at Wiley.

David Taylor

后浪出版公司

2019年6月